local_hospital

Studienzentrum Dr. Beate Schwarz

Address
lock Available on a paid plan

Skin and Connective Tissue Diseases

At Studienzentrum Dr. Beate Schwarz in Langenau, much of the research focuses on dermatology, especially psoriasis, atopic dermatitis, acne, rosacea, and skin ulcers. These studies are designed to test new treatments, compare them with current options, and better understand how to improve symptom control and skin healing.

  • Moderate-to-severe plaque psoriasis and related inflammatory skin disease
  • Atopic dermatitis, nummular dermatitis, and other eczema conditions
  • Hidradenitis suppurativa and chronic venous ulcers
  • Acne, rosacea, actinic keratosis, and candidiasis of the skin

The site is actively involved in evaluating therapies that may reduce inflammation, relieve itch, support wound closure, and improve day-to-day quality of life for people with chronic skin diseases.

Immune System Diseases

Another major area of research at this health care site is immune-mediated disease, with trials centered on conditions such as chronic spontaneous urticaria, psoriatic arthritis, and severe forms of atopic dermatitis. The goal is to assess whether new therapies can more effectively control immune-driven symptoms and improve patient outcomes.

  • Chronic spontaneous urticaria and itch-related disease
  • Active psoriatic arthritis
  • Moderate-to-severe atopic dermatitis
  • Immune-related inflammation linked to chronic skin disorders

These trials commonly compare emerging treatments with placebo or existing care to better define treatment effectiveness and safety in immune system diseases.

Nervous System Diseases

The research portfolio also includes studies in nervous system diseases, particularly conditions where nerve-related symptoms such as persistent itch play an important role. This includes work on notalgia paresthetica, where investigators are exploring whether new therapies can reduce discomfort and improve symptom control.

  • Moderate-to-severe pruritus associated with notalgia paresthetica
  • Persistent itch and sensory symptoms affecting daily comfort
  • Symptom relief in chronic neurocutaneous conditions

These studies aim to improve understanding of difficult-to-treat itch and to identify better ways to manage long-lasting nerve-related skin symptoms.

Parasitic Diseases

Research at the site also covers parasitic diseases, including scabies, a contagious skin condition that causes intense itching and irritation. The trials in this area focus on evaluating treatment effectiveness and confirming that new or existing therapies can clear infection-related skin symptoms.

  • Scabies treatment and symptom resolution
  • Clinical response after topical therapy
  • Improving control of itch and skin irritation caused by infestation

These studies are intended to support better treatment choices for patients affected by parasitic skin infections.

Site Overview

assignment
21
connected trials
corporate_fare
11
sponsors
science
22
IMPs

Activity Indicator

Last 6 months

2
Trials started
New activity detected vs previous period.
0
Trials started 6–12 months ago
21
Total trials linked
Highly Active
trending_upGrowing+100%
2
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 3 therapeutic areas and 15 of 22 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
7
Sponsors (total)
11
Active sponsors
5

Sponsor Network

Top 5 by active trials.

lock +4 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +5 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 2 161 other sites in Germany

description
Trial volume
21
Outperforms 90% of sites
public
Therapeutic diversity
3areas
Outperforms 79% of sites
groups
Sponsor diversity
11sponsors
Outperforms 88% of sites

Therapeutic Area Benchmark — Germany

Select a therapeutic area to compare against other sites in Germany.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Germany

Market Share

Country: Germany

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Studienzentrum Dr. Beate Schwarz

lock Showing 1 of 21 trials — the rest is available on a paid plan.

IMP list

lock Showing 1 of 22 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Jnj-772421134Unknown2024-01-182025-05-08

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.